2024 fibrolamellar calendars
Thanks to the efforts of FCF’s Patient & Caregiver Advisory Board, we will be producing fibrolamellar calendars in 2024!
FCF funds grant continuation at University of Washington
FCF has awarded a grant for additional studies to be conducted by John Scott, PhD of the University of Washington in Seattle. As the Chair of the Department of Pharmacology, Dr. Scott has been a key leader of a multi-disciplinary team working on FLC at the University of Washington and the Fred Hutchinson Cancer Center …
Thank you to Stone Point Capital!
A heartfelt thank you goes out to Stone Point Capital, as well as the sponsors and participants in the 2023 Stone Point Capital Charity Golf Tournament. Since 2009 Stone Point Capital has dedicated the proceeds from its annual charity event to FCF. This years event, held in Connecticut on October 2nd, raised a record amount …
October is Liver Cancer Awareness Month
October is Liver Cancer Awareness Month, a time to show support for those who have heard the terrifying words – “you have liver cancer”. It is also a vital opportunity raise awareness and funds to improve the detection and treatment of these diseases. There are several types of primary liver cancers. Hepatocellular carcinoma (HCC) and …
September 30 is Rare Cancer Day
Spearheaded by the National Organization of Rare Disorders’ (NORD) Rare Cancer Coalition, Rare Cancer Day is observed on September 30 each year to highlight the challenges facing rare cancer patients and the need for greater research funding. Rare cancers are those affecting fewer than 40,000 people per year in the US. Because of their low …
September is Childhood Cancer Awareness month
While childhood cancer is rare, it is the leading disease-related cause of death in children and adolescents. Worldwide, approximately 400,000 children and adolescents develop cancer each year, only half of whom are diagnosed. In recognition of this issue, September is internationally recognized as “Childhood Cancer Awareness Month”. During this time, organizations and families around the …
Research partnership established with Dana-Farber
FCF is please to announce that it has established a new partnership with the Center for Patient Derived Models (CPDM) at the Dana-Farber Cancer Institute in Boston. The purpose of this new relationship is to expand, characterize and distribute existing models of FLC; create new FLC models; and make them readily available to the researcher …
FCF funds planned clinical trial at Johns Hopkins
We are pleased to announce that FCF has awarded Dr. Marina Baretti and Dr. Mark Yarchoan of Johns Hopkins University a grant to launch a new clinical trial for FLC patients. Both investigators have extensive experience in treating patients with FLC and in the development of immunotherapies. They already have collaborated closely on the clinical …
FCF establishes partnership with Dracen Pharmaceuticals
FCF is pleased to announce that it has entered into a partnership agreement with Dracen Pharmaceuticals, Inc. to supply a glutamine antagonist pro-drug, DRP-104 (sirpiglenastat), for a planned clinical trial in fibrolamellar patients. Under the agreement, Dracen will provide the product, as well as regulatory and operational support for the trial. In fibrolamellar carcinoma, recent …